Androgens in Patients With Luminal B and HER2 Breast Cancer Might Be a Biomarker Promoting Anti-PD-1 Efficacy

被引：8

作者：

Li, Peng ^{[1
,2
]}

Yuan, Wenhui ^{[1
,2
]}

Wu, Ruan ^{[3
]}

Zeng, Chuqian ^{[4
]}

Li, Ke ^{[5
]}

Lu, Ligong ^{[1
]}

机构：

[1] Jinan Univ, Zhuhai Peoples Hosp Affiliated, Zhuhai Inst Translat Med, Guangdong Prov Key Lab Tumor Intervent Diag & Trea, Zhuhai, Peoples R China

[2] Jinan Univ, Biomed Translat Res Inst, Fac Med Sci, Guangzhou, Peoples R China

[3] Anhui Prov Ctr Dis Control & Prevent, Hefei, Peoples R China

[4] Jinan Univ, Affiliated Hosp 1, Guangzhou, Peoples R China

[5] Guangdong Second Prov Gen Hosp, Dept Infect Dis, Guangzhou, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2022年 / 12卷

关键词：

androgens; androgen receptor; breast cancer; immune checkpoint receptors; gamma delta T cells; RECEPTORS; EXPRESSION; THERAPY; CELLS;

D O I：

10.3389/fonc.2022.917400

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Endocrine therapy is considered as an effective strategy for estrogen and progestogen receptor (ER and PR)-positive breast cancer (BRCA) patients, whereas resistance to these agents is the major cause of BRCA mortality in women. Immune checkpoint receptor (ICR) blockade is another approach to treat BRCA, but the response rate of this approach for non-triple-negative breast cancer (non-TNBC) is relatively low. Recently, the androgen receptor (AR) has been identified as a tumor suppressor in ER-positive BRCA; however, the relationship between the levels of androgens and ICRs on T cells in BRCA is unclear. We observed that testosterone and dihydrotestosterone (DHT) in patients with HER2 and Luminal B were significantly lower than those in healthy controls, and the expression of AR has significant correlation with overall survival (OS) advantage for Luminal B patients. Moreover, testosterone and DHT were positively correlated with the PD-1 expression on V delta 1(+) T cells in HER2 and Luminal B patients. These results suggest a potential approach of combining androgens with PD-1 blockade for treating HER2 and Luminal B breast cancer.

引用

页数：8